The US Food and Drug Administration (FDA) has granted approval to Israel-based Teva Pharmaceutical Industries for its AJOVY (fremanezumab-vfrm) injection intended for the preventive treatment of migraine in adults, it was reported yesterday.
The a humanised monoclonal antibody that binds to calcitonin gene-related peptide ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options.
The product was assessed in two Phase III, placebo-controlled clinical trials that enrolled patients with disabling migraine and was studied as both a stand-alone preventive treatment and in combination with oral preventive treatments. In these trials, patients experienced a decrease in monthly migraine days during a 12-week period. The most common adverse reactions (less than 5% and greater than placebo) were injection site reactions.
The U.S. Wholesale Acquisition Cost (WAC) of AJOVY is USD575 per monthly dose and USD1,725 per quarterly dose. AJOVY will be available through retail and specialty pharmacies in approximately two weeks.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial